Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Nov;76(11):1532-1539.
doi: 10.1002/acr.25393. Epub 2024 Aug 14.

Childhood Arthritis and Rheumatology Research Alliance Biologic Disease-Modifying Antirheumatic Drug Consensus Treatment Plans for Refractory Moderately Severe Juvenile Dermatomyositis

Stacey E Tarvin  1 , Matthew A Sherman  2 , Hanna Kim  3 , Nayimisha Balmuri  4 , Amanda G Brown  5 , Albert Chow  6 , Harry L Gewanter  7 , Marietta M de Guzman  8 , Adam M Huber  9 , Susan Kim  10 , Marisa S Klein-Gitelman  11 , Megan M Perron  12 , Angela Byun Robinson  13 , Sara E Sabbagh  14 , Sonia Savani  15 , Susan Shenoi  16 , Jacob Spitznagle  16 , Cory Stingl  17 , Grant Syverson  18 , Heather Tory  19 , Charles Spencer  20 ; Childhood Arthritis and Rheumatology Research Alliance Juvenile Dermatomyositis Workgroup
Collaborators, Affiliations

Childhood Arthritis and Rheumatology Research Alliance Biologic Disease-Modifying Antirheumatic Drug Consensus Treatment Plans for Refractory Moderately Severe Juvenile Dermatomyositis

Stacey E Tarvin et al. Arthritis Care Res (Hoboken). 2024 Nov.

Abstract

Objective: The objective was to develop consensus treatment plans (CTPs) for patients with refractory moderately severe juvenile dermatomyositis (JDM) treated with biologic disease-modifying antirheumatic drugs (bDMARDs).

Methods: The Biologics Workgroup of the Childhood Arthritis and Rheumatology Research Alliance JDM Research Committee used case-based surveys, consensus framework, and nominal group technique to produce bDMARD CTPs for patients with refractory moderately severe JDM.

Results: Four bDMARD CTPs were proposed: tumor necrosis factor α (TNFα) inhibitor (adalimumab or infliximab), abatacept, rituximab, and tocilizumab. Each CTP has different options for dosing and/or route. Among 76 respondents, consensus was achieved for the proposed CTPs (93% [67 of 72]) as well as for patient characteristics, assessments, outcome measures, and follow-up. By weighted average, respondents indicated that they would most likely administer rituximab, followed by abatacept, TNFα inhibitor, and tocilizumab.

Conclusion: CTPs for the administration of bDMARDs in refractory moderately severe JDM were developed using consensus methodology. The implementation of the bDMARD CTPs will lay the groundwork for registry-based prospective comparative effectiveness studies.

PubMed Disclaimer

References

REFERENCES

    1. Rider LG, Nistala K. The juvenile idiopathic inflammatory myopathies: pathogenesis, clinical and autoantibody phenotypes, and outcomes. J Intern Med 2016;280(1):24–38.
    1. Mendez EP, Lipton R, Ramsey‐Goldman R, et al; NIAMS Juvenile DM Registry Physician Referral Group. US incidence of juvenile dermatomyositis, 1995‐1998: results from the national institute of arthritis and musculoskeletal and skin diseases registry. Arthritis Rheum 2003;49(3):300–305.
    1. Shah M, Mamyrova G, Targoff IN, et al; with the Childhood Myositis Heterogeneity Collaborative Study Group. The clinical phenotypes of the juvenile idiopathic inflammatory myopathies. Medicine (Baltimore) 2013;92(1):25–41.
    1. Stringer E, Singh‐Grewal D, Feldman BM. Predicting the course of juvenile dermatomyositis: significance of early clinical and laboratory features. Arthritis Rheum 2008;58(11):3585–3592.
    1. Ravelli A, Trail L, Ferrari C, et al. Long‐term outcome and prognostic factors of juvenile dermatomyositis: a multinational, multicenter study of 490 patients. Arthritis Care Res (Hoboken) 2010;62(1):63–72.

LinkOut - more resources